The impact of phosphatidylserine exposure on cancer cell membranes on the activity of the anticancer peptide HB43
© 2021 Federation of European Biochemical Societies..
HB43 (FAKLLAKLAKKLL) is a synthetic peptide active against cell lines derived from breast, colon, melanoma, lung, prostate, and cervical cancers. Despite its remarkable spectrum of activity, the mechanism of action at the molecular level has never been investigated, preventing further optimization of its selectivity. The alternation of charged and hydrophobic residues suggests amphipathicity, but the formation of alpha-helical structure seems discouraged by its short length and the large number of positively charged residues. Using different biophysical and in silico approaches we show that HB43 is completely unstructured in solution but assumes alpha-helical conformation in the presence of DPC micelles and liposomes exposing phosphatidylserine (PS) used as mimics of cancer cell membranes. Membrane permeabilization assays demonstrate that the interaction leads to the preferential destabilization of PS-containing vesicles with respect to PC-containing ones, here used as noncancerous cell mimics. ssNMR reveals that HB43 is able to fluidify the internal structure of cancer-cell mimicking liposomes while MD simulations show its internalization in such bilayers. This is achieved by the formation of specific interactions between the lysine side chains and the carboxylate group of phosphatidylserine and/or the phosphate oxygen atoms of targeted phospholipids, which could catalyze the formation of the alpha helix required for internalization. With the aim of better understanding the peptide biocompatibility and the additional antibacterial activity, the interaction with noncancerous cell mimicking liposomes exposing phosphatidylcholine (PC) and bacterial mimicking bilayers exposing phosphatidylglycerol (PG) is also described.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:289 |
|---|---|
| Enthalten in: |
The FEBS journal - 289(2022), 7 vom: 10. Apr., Seite 1984-2003 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herrera-León, Claudia [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 06.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/febs.16276 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333051092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333051092 | ||
| 003 | DE-627 | ||
| 005 | 20231225220835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/febs.16276 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333051092 | ||
| 035 | |a (NLM)34767285 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herrera-León, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of phosphatidylserine exposure on cancer cell membranes on the activity of the anticancer peptide HB43 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 06.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Federation of European Biochemical Societies. | ||
| 520 | |a HB43 (FAKLLAKLAKKLL) is a synthetic peptide active against cell lines derived from breast, colon, melanoma, lung, prostate, and cervical cancers. Despite its remarkable spectrum of activity, the mechanism of action at the molecular level has never been investigated, preventing further optimization of its selectivity. The alternation of charged and hydrophobic residues suggests amphipathicity, but the formation of alpha-helical structure seems discouraged by its short length and the large number of positively charged residues. Using different biophysical and in silico approaches we show that HB43 is completely unstructured in solution but assumes alpha-helical conformation in the presence of DPC micelles and liposomes exposing phosphatidylserine (PS) used as mimics of cancer cell membranes. Membrane permeabilization assays demonstrate that the interaction leads to the preferential destabilization of PS-containing vesicles with respect to PC-containing ones, here used as noncancerous cell mimics. ssNMR reveals that HB43 is able to fluidify the internal structure of cancer-cell mimicking liposomes while MD simulations show its internalization in such bilayers. This is achieved by the formation of specific interactions between the lysine side chains and the carboxylate group of phosphatidylserine and/or the phosphate oxygen atoms of targeted phospholipids, which could catalyze the formation of the alpha helix required for internalization. With the aim of better understanding the peptide biocompatibility and the additional antibacterial activity, the interaction with noncancerous cell mimicking liposomes exposing phosphatidylcholine (PC) and bacterial mimicking bilayers exposing phosphatidylglycerol (PG) is also described | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a NMR | |
| 650 | 4 | |a anticancer peptide | |
| 650 | 4 | |a biomembranes | |
| 650 | 4 | |a membrane permeabilization | |
| 650 | 4 | |a molecular dynamics | |
| 650 | 4 | |a paramagnetic relaxation enhancement | |
| 650 | 7 | |a Antimicrobial Cationic Peptides |2 NLM | |
| 650 | 7 | |a Lipid Bilayers |2 NLM | |
| 650 | 7 | |a Phosphatidylglycerols |2 NLM | |
| 650 | 7 | |a Phosphatidylserines |2 NLM | |
| 700 | 1 | |a Ramos-Martín, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Antonietti, Viviane |e verfasserin |4 aut | |
| 700 | 1 | |a Sonnet, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amelio, Nicola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The FEBS journal |d 2005 |g 289(2022), 7 vom: 10. Apr., Seite 1984-2003 |w (DE-627)NLM15295631X |x 1742-4658 |7 nnns |
| 773 | 1 | 8 | |g volume:289 |g year:2022 |g number:7 |g day:10 |g month:04 |g pages:1984-2003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/febs.16276 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 289 |j 2022 |e 7 |b 10 |c 04 |h 1984-2003 | ||